Antisecretory factor effectively and safely stops childhood diarrhoea: a placebo-controlled, randomised study.
Acta Paediatr
; 103(6): 659-64, 2014 Jun.
Article
en En
| MEDLINE
| ID: mdl-24484450
ABSTRACT
AIM:
We studied the response to high doses of egg yolk containing antisecretory factor (B221® , Salovum®) in young children with acute diarrhoea, presenting to the Children's Hospital, Lahore, Pakistan.METHODS:
In a randomised, placebo-controlled trial, 36 children aged 7 to 60 months with acute diarrhoea of unknown aetiology, with mild-to-moderate dehydration, were randomised to the Salovum® or placebo groups. Initially, 16 grams of Salovum® or ordinary egg yolk (placebo) mixed in oral rehydration salts was given, followed by 8 g every 5 h until recovery. The number and consistency of stools were recorded.RESULTS:
The two groups were comparable in age, gender, duration of diarrhoea, hydration and nutritional status, although the proportion with watery stools was higher in the Salovum® group (p = 0.04). Reduction in the frequency of stools was seen at 7 versus 18 h (p < 0.0001) and normalising of stool consistency was 10 versus 18 h, p < 0.03) in the Salovum® and placebo groups. The overall effect was 35 versus 70 h in the two groups (p = 0.001). No side effects were reported.CONCLUSION:
High doses of AF in the form of Salovum® effectively and safely reduce childhood diarrhoea of a likely broad aetiology.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
/
2_ODS3
/
3_ND
Problema de salud:
1_doencas_transmissiveis
/
2_enfermedades_transmissibles
/
3_diarrhea
/
3_neglected_diseases
Asunto principal:
Neuropéptidos
/
Diarrea
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Límite:
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
País/Región como asunto:
Asia
Idioma:
En
Revista:
Acta Paediatr
Año:
2014
Tipo del documento:
Article
País de afiliación:
Pakistán